The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Lecanemab: Appropriate Use Recommendations
Open accessAbstract
Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world clinical practice. Community dwelling patients with AD differ from those participating in clinical trials. Administration of lecanemab at clinical trial sites by individuals experienced with monoclonal antibody therapy also differs from the community clinic-based administration of lecanemab. These AURs use clinical trial data as well as research and care information regarding AD to help clinicians administer lecanemab with optimal safety and opportunity for effectiveness. Safety and efficacy of lecanemab are known only for patients like those participating in the phase 2 and phase 3 lecanemab trials, and these AURs adhere closely to the inclusion and exclusion criteria of the trials. Adverse events may occur with lecanemab including amyloid related imaging abnormalities (ARIA) and infusion reactions. Monitoring guidelines for these events are detailed in this AUR. Most ARIA with lecanemab is asymptomatic, but a few cases are serious or, very rarely, fatal. Microhemorrhages and rare macrohemorrhages may occur in patients receiving lecanemab. Anticoagulation increases the risk of hemorrhage, and the AUR recommends that patients requiring anticoagulants not receive lecanemab until more data regarding this interaction are available. Patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially APOE4 homozygotes, are at higher risk for ARIA, and the AUR recommends APOE genotyping to better inform risk discussions with patients who are lecanemab candidates. Clinician and institutional preparedness are mandatory for use of lecanemab, and protocols for management of serious events should be developed and implemented. Communication between clinicians and therapy candidates or those on therapy is a key element of good clinical practice for the use of lecanemab. Patients and their care partners must understand the potential benefits, the potential harms, and the monitoring requirements for treatment with this agent. Culture-specific communication and building of trust between clinicians and patients are the foundation for successful use of lecanemab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lecanemab has a boxed warning for serious and symptomatic ARIA and requires testing for APOE ε4 prior to initiation as homozygosity increases risk.(510)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [510]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, anti-amyloid monoclonal antibodies require the confirmation of amyloid-β pathology from PET or CSF before initiating therapy45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, although patients with early-stage AD may be candidates for anti-amyloid therapies15–17, the coexistence of pathology from other etiologies, such as VD, can increase the risk of amyloid-related imaging abnormalities18.”
From AI-based differential diagnosis of dementia etiologies on multimodal data (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The risk of developing these potentially serious adverse effects is higher in APOEε4 carriers, particularly homozygotes, and current recommendations are that patients are genotyped for APOE before starting these therapies to offer a balanced benefit–risk discussion190.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [190]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma biomarkers may therefore have an important role in reducing the patient burden associated with the initiation of anti-amyloid-β therapies for AD, which at present require biomarker confirmation with PET or CSF, as well as serial magnetic resonance imaging to monitor for adverse events45,46.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Individuals with two copies of the APOE‐e4 gene are at increased risk of developing ARIA.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · PubMed · Cited by 21,012
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J., & Wouters, E. (2015) · Gerontology · doi:10.1159/000430949 · Cited by 19,852
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. J. (2014) · Gerontology · doi:10.1159/000362720 · Cited by 19,007
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citationLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Self-citationMR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging
Fazekas, F., Chawluk, J. B., Alavi, A. A., Hurtig, H. I., & Zimmerman, R. A. (1987) · American Journal of Roentgenology · doi:10.2214/ajr.149.2.351 · Cited by 5,327
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, S. C, editors. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer's disease. 15th Clinical Trials on Alzheimer's Disease Conference; 2022; San Francisco, CA USA.
Cited by
Sorted by citations
Items 501–600 of 961
Factors associated with discordant visual and quantitative amyloid PET results
Guevara, J. E., Matusz, E. F., Wang, W., DeSimone, J. C., Yawer, B. A., Fiala, J. A., Levy, S., Arias, F., Rayaprolu, S., Barker, W. W., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70241 · Cited by 2
Roslan, A. A., Shah, T. M. H. T. M., Saffian, S. M., John, L. J., Ramli, M. D. C., Nassir, C. M. N. C. M., Mahadi, M. K., & Hein, Z. M. (2026) · Pharmaceuticals · doi:10.3390/ph19010166 · Cited by 2
Moon, S. Y., Ta-Fu, C., Lee, B., Moon, W. J., Kandiah, N., Kumar, S., Park, Y. H., Inaba, K., & Dash, A. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100477 · Cited by 3
From consortia discovery to biotech creation: An innovative approach to next‐gen Alzheimer's drugs
Giardina, S. F., Culver, A. E., Ahmed, C., Mirescu, C., Oblak, A. L., Brosch, J. R., Clayton, B., Dage, J. L., Lamb, B. T., Richardson, T. I., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71165 · Cited by 2
Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIA
Johnson, L. A., Saito, K., Pallerla, A. V., Funnell, J. L., Ezzo, A. R., Song, C. M., Harrison, D. A., Norton, N. J., Moore, L. C., Eldik, L. J. V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68921-3 · Cited by 5
Zilioli, A., Mohanty, R., Rosenberg, A., Matton, A., Granberg, T., Hagman, G., Spallazzi, M., Ferreira, D., Kivipelto, M., & Westman, E. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01972-2 · Cited by 2
Cánovas, R., Fowler, C. J., Feizpour, A., Doré, V., Bourgeat, P., Saad, Z. S., Triana‐Baltzer, G., Kolb, H. C., Vandijck, M. L. J., Kollmorgen, G., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71145 · Cited by 3
Chen, C., Lee, J. R., Park, K. H., Hu, C., Mok, V., Senanarong, V., Inaba, K., & Dash, A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71230 · Cited by 2
Marano, G., Cas, R. D., Ippoliti, I., Caffarra, P., Locuratolo, N., Vanacore, N., & Ancidoni, A. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08829-4 · Cited by 2
Wluka, V. A., DeSpenza, T., Liu, A. J., & Bramall, A. N. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1736687 · Cited by 2
Liu, P., Liu, J., Wang, J., Du, Y., Liu, Z., Zhang, H., Zhu, A., Zhang, G., Meng, X., Zhao, C., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100542 · Cited by 3
Eligibility for amyloid targeting therapies among primary care patients with cognitive symptoms
Bolmsjö, B. B., Djärf, J. B., van Westen, D., Schindler, S. E., Fawad, A., Collij, L. E., Smith, R., Mattsson, N., Stomrud, E., Tideman, P., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02019-2 · Cited by 2
Qudoos, M. A., & Elliott, D. P. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.98 · Cited by 2
The mechanisms and strategies for Alzheimer’s disease prevention: An update
Han, M., Wang, N., Song, M., Liu, C., Wu, Y., Yin, J., Jin, L., Jin, W., & Gao, Z. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.007 · Cited by 3
Zhang, J., Zhang, J., Ding, J., Zhang, X., Wang, Y., Wei, W., Chai, Y., Zhang, S., & Chen, X. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71451 · Cited by 3
Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care
Morbelli, S. D., Bozzali, M., Cagnin, A., Cecchin, D., Chiti, A., & Filippi, M. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13874-2 · Cited by 2
Reduced Effect of APOE4 on White Matter Microstructure in an American Indian Community
Labounek, R., Matheson, M. J., Strong, C., Petersen, A. J., Hill, A., Robertson, A. J., Hansen, A., Block, A. D., Henderson, J. N., Nestrašil, I., et al. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200418 · Cited by 2
Clinical Practice Outcomes With Lecanemab for Alzheimer Disease
Liu, A., Moghadam, A. A., Alam, M. S., Lutz, M. W., Navarra, A., Luo, S., Wang, L., Petrella, J. R., Whitson, H. E., O’Brien, R., et al. (2026) · Neurology Open Access · doi:10.1212/wn9.0000000000000121 · Cited by 2
Clinical Efficacy in Individual Patients Treated with Lecanemab
Gauthier, S. G., Therriault, J., & Rosa‐Neto, P. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.58 · Cited by 2
Greer, O., Cheng, R., Tamres, L. K., Mattos, M. K., Morris, J. L., Knox, M. L., & Lingler, J. H. (2023) · Geriatric Nursing · doi:10.1016/j.gerinurse.2023.07.007 · Cited by 3
Asahara, Y., Kameyama, M., Ishii, K., & Ishibashi, K. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.122782 · Cited by 2
Here's How Coverage for Amyloid PET Is Changing
Burling, S. (2023) · Neurology Today · doi:10.1097/01.nt.0000998136.35252.f5 · Cited by 2
Pressman, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00119-6 · Cited by 2
Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging
By, S., Kahl, A., & Cogswell, P. M. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29462 · Cited by 2
Lo, A. X., Shih, R. D., Rackman, A. S., & Kennedy, R. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19099 · Cited by 3
Sato, K., Niimi, Y., Ihara, R., Iwata, A., & Iwatsubo, T. (2024) · Biomedicines · doi:10.3390/biomedicines12081870 · Cited by 2
Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis
Howe, M. D., Caruso, M. R., Manoochehri, M., Kunicki, Z. J., Emrani, S., Rudolph, J. L., Huey, E. D., Salloway, S., Oh, H., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14207 · Cited by 1
Self-citationSato, K., Niimi, Y., Ihara, R., Iwata, A., & Iwatsubo, T. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240623 · Cited by 2
Scuteri, D., Pierobon, D., Pagliaro, M., Hamamura, K., Hayashi, T., Pignolo, L., Nicotera, P., Bagetta, G., & Corasaniti, M. T. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101253 · Cited by 2
Prevalence and associations of cerebral microbleeds in an Australian Memory clinic cohort
Wrigley, S., Cody, R., Amadoru, S., Huynh, A. L. H., Galante, O., Mandrawa, C., Yassi, N., & Yates, P. A. (2024) · Internal Medicine Journal · doi:10.1111/imj.16614 · Cited by 3
Jutten, R. J., Ho, E., Karpouzian‐Rogers, T., Hulle, C. V., Carlsson, C. M., Dodge, H. H., Nowinski, C. J., Gershon, R. C., Weıntraub, S., & Rentz, D. M. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70046 · Cited by 2
Kim, J., Kim, E., Park, M., Bae, Y. J., Suh, C. H., You, S., Yim, Y., Lee, H., Choi, J. W., Oh, S. W., et al. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2024.0147 · Cited by 3
Pulido-Correa, V., Hernandez, A., Wind, E. J., Zhu, Y., Vogel, C., Binu, S., Jeneske, M., Kuni, D., Chiduruppa, V., Echeverria, B., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261445916 · Cited by 3
Disease-modifying effect of donepezil on APP/PS1 mice at different stages of Alzheimer’s disease
Zueva, I. V., Belyaev, G. P., & Petrov, K. A. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05310-2 · Cited by 2
Chiabotti, P. S., Nasuti, M., Rouaud, O., & Allali, G. (2025) · Journal of Alzheimer's Disease · doi:10.1177/13872877251342266 · Cited by 2
Accelerated MRI Sequences for Intracranial Hemorrhage Screening
Loftus, J. R., McClelland, A. C., Hsu, K. A., Nayak, G. K., Bruno, M. T., Jachung, R., Keerthivasan, M., Sadowski, M. J., & Shepherd, T. M. (2025) · Investigative Radiology · doi:10.1097/rli.0000000000001229 · Cited by 2
Advancing Care in Alzheimer’s Disease: Current Treatments and Their Impact on Quality of Life
Yashaeva, L., Montoya, M., Joshi, J., Stephens, A., McNulty, O., & Kaur, G. (2025) · Cureus · doi:10.7759/cureus.90527 · Cited by 5
Alsaadi, T. M., Almadani, A., Alrukn, S., Hassan, A., Sarathchandran, P., Shatila, A. O., Szólics, M., Benito, D., İnce, S., & Krieger, D. W. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00833-8 · Cited by 2
Add-on combination therapy with monoclonal antibodies: Implications for drug development
Cummings, J. L., Burstein, A. H., & Fillit, H. M. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100359 · Cited by 2
Self-citationChen, A., Li, Q., Huang, Y., Li, Y., Chuang, Y.-N., Hu, X., Guo, S., Wu, Y., Guo, Y. M., & Bian, J. (2024) · medRxiv · doi:10.1101/2024.02.10.24302621 · Cited by 2
Díaz, A. G., Sarracco, E., Possenti, A., Kitchen-Smith, I., Chia, S., Menzies, J., Stephenson, G., Cataldi, R., Yahya, K., Bian, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.30.610591 · Cited by 2
Parent, O., Alasmar, Z., Osborne, S., Bussy, A., Costantino, M., Fouquet, J. P., Quesada, D., Pastor-Bernier, A., Fajardo-Valdez, A., Binette, A. P., et al. (2025) · medRxiv · doi:10.1101/2025.06.10.25329342 · Cited by 6
Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era
Coraglia, F., Cecchetti, G., Rugarli, G., Spinelli, E. G., Ghirelli, A., Pisano, S., Canu, E., Filippi, M., & Agosta, F. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02089-2 · Cited by 1
Mantyh, W. G., Block, A. D., Castro, M. R., Hansen, A., Matheson, M. J., Strong, C., Hill, A., Caycı, Z., & Henderson, J. N. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.38221 · Cited by 1
Alzheimer’s Disease Stage Transitions Among United States Veterans
Morin, P., Aguilar, B. J., Li, X., Chen, J., Berlowitz, D. R., Zhang, R. J., Monfared, A. A. T., Zhang, Q., & Xia, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230850 · Cited by 1
Monoclonal antibody therapy in Alzheimer’s disease: an overview and vision
Bentley, J. H., Bishop, L. E., & Broussard, J. I. (2024) · Brain Network and Modulation · doi:10.4103/bnm.bnm_14_23 · Cited by 2
Stettenbauer, E. G., Berry, S. D., Lee, Y., Zullo, A. R., & Daiello, L. A. (2024) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2024.105192 · Cited by 1
Lecanemab: A novel disease-modifying drug treatment for Alzheimer’s disease
Bhanwra, S., & Mahajan, S. S. (2024) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_17_24 · Cited by 1
Morehouse, C. R., Hendriks, S., Rabbee, N., & Kim, S. Y. H. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.11.011 · Cited by 1
Ricaurte‐Fajardo, A., Ivanidze, J., Zhang, D., Mahmud, M., Yasen, W., Ravdin, L., Pahlajani, S. S., de Leon, M., Nordvig, A. S., & Chiang, G. C.-Y. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8654 · Cited by 1
Current Drugs Used: Classification and Pharmacology
Swain, S. S., Mude, L., Roychowdhury, P., Karri, V. V. S. R., Kuppusamy, G., Gobinath, M., & Subramaniyan, V. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_8 · Cited by 1
Ethical challenges associated with the early detection of Alzheimer's disease
Milne, R., Costa, A., & Brayne, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-822240-9.00019-3 · Cited by 1
Deverka, P. A., Arias, J. J., Lin, G. A., Zwerling, J. L., & Phillips, K. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251329394 · Cited by 2
APOE ε4 and Alzheimer's disease risk in Vietnamese populations
Block, A. D., Petersen, A. J., Hansen, A., Matheson, M. J., Nguyen, P. A. T., Trần, V. L., Nguyen, B. T., Nguyen, B. T., Nguyen, B. T. T., Trần, H. T., et al. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251334066 · Cited by 1
Querfurth, H. W., Lemere, C. A., Ciola, J., Havas, D., Xia, W., & Lee, H. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083473 · Cited by 2
Karneboge, J. N., von Boehn, F., & Haberstroh, J. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70112 · Cited by 1
Psychological impact of biomarker-assisted diagnosis of Alzheimer's disease
Landry, A., Elsliger, S., Gaudet, J., Al‐Shamaa, S., & Chamard-Witkowski, L. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251341587 · Cited by 1
Assessing accuracy for multi-class classification when subclasses are involved
Nan, N., & Tian, L. (2025) · Statistical Methods in Medical Research · doi:10.1177/09622802251343600 · Cited by 1
New Frontier, New Challenges—Recognizing and Managing Adverse Effects of Antiamyloid Therapies
Rech, M. A., Aggarwal, N. T., & Hwang, U. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.2242 · Cited by 1
Katel, S., Cicalo, J., Vasciaveo, V., Vecchio, L. M., Carrión, J., Leann, M., Huerta, P. T., Choksi, J. D., Aubert, I., Marambaud, P., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101563 · Cited by 2
Parks, A. L., Thacker, A., Dohan, D. P., Gomez, L. A. R., Gale, S. A., Johnson, K. G., Ritchie, C. S., Shah, S. J., & Paladino, J. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70150 · Cited by 2
Lin, G.-B., Liu, H.-H., Kuo, Y.-Y., Chen, Y.-M., Hsu, F.-T., Wang, Y., Kung, Y., Ching, C., & Chao, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010236 · Cited by 1
Nemeh, G., Doede, A. L., & Cuomo, R. E. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100288 · Cited by 1
Garnier‐Crussard, A., Landeau, B., Mézenge, F., Gonneaud, J., Roquet, D., Cotton, F., & Chételat, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-23371-7 · Cited by 1
Wagemann, O., Tesky, V. A., Schall, A., Nübling, G., Wlasich, E., Hüer, T., Walendzik, A., Weitzel, M., Giebel, G. D., Raszke, P., et al. (2025) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2708-3648 · Cited by 1
From Lesion to Decision: AI for ARIA Detection and Predictive Imaging in Alzheimer’s Disease
Christodoulou, R. C., Papageorgiou, P. S., Sarquis, M. D., Rivera, L., Gonzalez, C. M., Eller, D. W., Rivera, G., Petrou, V., Vamvouras, G., Vassiliou, E. K., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112739 · Cited by 2
Monoclonal Antibody Therapies in Alzheimer's Disease: A Guide for Emergency Physicians
Wrigley, S., Huynh, A. L. H., Amadoru, S., Zeimer, H., Tan, I., Woodward, M., Braitberg, G., Yates, P. A., & Shelton, C. J. A. (2025) · Emergency Medicine Australasia · doi:10.1111/1742-6723.70167 · Cited by 1
Wiest, R., Radojewski, P., Lieb, J., Psychogios, M., Benzinger, T. L. S., Franceschi, A. M., Wanke, I., Draganski, B., Kurz, F. T., & Lövblad, K. (2025) · Neurodegenerative Diseases · doi:10.1159/000549521 · Cited by 1
Rosenich, E., Olver, H., Cummins, H., Karlawish, J. H., & Lim, Y. Y. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251393714 · Cited by 1
Plasma biomarkers in neuropsychiatric syndromes: A narrative review
Ismail, Z., Guan, D. X., Babulal, G. M., Bateman, J. R., Cantillon, M., Creese, B., D’Antonio, F., Fischer, C. E., Gatchel, J. R., Ghahremani, M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251392185 · Cited by 3
Prelog, P. R., Zupan, M., Kramberger, M. G., & Frol, S. (2025) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000549621 · Cited by 1
Rubio‐Guerra, S., Sala, I., Sánchez‐Saudinós, M. B., Videla, L., Bejanin, A., Estanga, A., Ecay‐Torres, M., de Luis, C. L., Rami, L., Tort‐Merino, A., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70223 · Cited by 1
Immediate reactions to amyloid PET disclosure in Japanese older adults without dementia
Sato, K., Niimi, Y., Ihara, R., Ikeuchi, T., Ishii, K., Ito, K., Iwata, A., Kasuga, K., Kato, T., Kowa, H., et al. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70167 · Cited by 1
Tian, Q., Liu, M., Zhong, F., Liu, X., & Lü, Y. (2026) · BMC Neurology · doi:10.1186/s12883-025-04581-y · Cited by 1
Roth, S., Yan, J. T., Patru, M.-M., Mattke, S., Gustavsson, A., & Ortsäter, G. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251406909 · Cited by 1
Analysis of the dual role of amyloid-beta in Alzheimer’s disease through multi-omics integration
Guo, J., Lu, X., Qiu, L., Xue, W., Fu, H., Wang, K., & Wang, Y. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00872 · Cited by 2
Alzheimer Disease and the Utility of PET
Casper, A., & Bolin, J. D. (2026) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.271758 · Cited by 1
Treating Alzheimer's disease in a person living with HIV
Clifford, D. B., Benzinger, T. L. S., Han, J., Powles, S. T., Paczynski, M., Ances, B. M., & Campbell, J. W. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70259 · Cited by 1
The Double-Edged Sword Effect of the Fibrinolytic System in Alzheimer’s Disease
Tang, M., Liang, M., Zhang, X., Hong, C., & Ye, L. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01699-6 · Cited by 1
Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies
Haut, M. W., Teixeira, C. V. L., Worhunsky, P. D., Mehta, R. I., Malone, J. E., Ward, M., Keith, C. M., Phelps, H. E., Pockl, S., Rajabalee, N., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100519 · Cited by 1
Amyloid PET quantification with deep learning segmentation models without MRI
Chiu, S.-C., Lin, Y., McConathy, J., Lin, S.-Y., Fang, Y.-H. D., & Initiative, A. D. N. (2026) · EJNMMI Physics · doi:10.1186/s40658-026-00854-8 · Cited by 1
Navarra, A., Petrella, J. R., Liu, A. J., Ikramuddin, S. S., & Doraiswamy, P. M. (2026) · Cureus · doi:10.7759/cureus.105106 · Cited by 1
Patients’ choices and eligibility for anti‐amyloid therapy in Japan's universal insurance
Ihara, R., Kurihara, M., Hatano, K., Bannai, T., Shimasaki, R., Hatakeyama, A., Furuta, K., Suzuki, F., Tokumaru, A. M., Ishii, K., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70315 · Cited by 1
Caro, D. D., Rodriguez, S., Uhlmann, W. R., Goldman, J. S., McCain, S., Wetmore, J. B., Cabán, M., Chung, W. K., Roberts, J. S., Siegel, K., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261435633 · Cited by 1
Wang, J., Zhong, A., Xu, Q., Huang, H., Zhu, Y. H., Lu, J., Wang, M., Jiang, J., Li, C., Ni, M., et al. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02570-0 · Cited by 1
Genetic analysis of neurodegenerative diseases
Grassano, M., Schindler, A. B., Traynor, B. J., & Scholz, S. W. (2026) · Journal of Clinical Investigation · doi:10.1172/jci199840 · Cited by 1
Older Adults, Anti‐Amyloid Therapy, and Frailty: What Oncology Can Teach Us
Borda, M. G., O'Hara‐Veintimilla, K., & Aarsland, D. (2026) · European Journal of Neurology · doi:10.1111/ene.70567 · Cited by 1
Bigjahan, B., Cavallari, M., & Barisano, G. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1719740 · Cited by 3
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
Diffusion weighted imaging abnormalities and cerebral ischemia in a cohort of patients on lecanemab
Ryan, D., Lutz, M. W., Sides, T. R., O’Brien, R., & Johnson, K. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71392 · Cited by 2
Ó’Caoimh, R., Marks, E., & O’Donovan, M. R. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261441514 · Cited by 1
Use of anti–amyloid‐β monoclonal antibodies in persons with Down syndrome Alzheimer's disease
Farrell, C., Saini, F., Beidas, M. M., Ryan, N. S., Strydom, A., & Wiseman, F. K. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71404 · Cited by 1
Kulkarni, H. R. (2026) · PET Clinics · doi:10.1016/j.cpet.2026.03.003 · Cited by 1
Klafki, H., Derad, C., Hohberg, M., Asendorf, T., Esselmann, H., Hassan, M. M., Hansen, N., Celano, C. M., Heinemann, S., Kutschka, I., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70362 · Cited by 1
Yan, Y., Hu, D., Kong, L., Li, K., Su, J., Wu, Y., Zhan, H., Hong, Z. Q., Sun, Y., Dou, X., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100600 · Cited by 1
PET/MR: history, current state, and technology
An, H. (2026) · British Journal of Radiology · doi:10.1093/bjr/tqag122 · Cited by 1
Now is the time: the need to update guidance to expand access to APOE genetic testing
Uhlmann, W. R., Chan, A. K., & Goldman, J. S. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1808512 · Cited by 1
Li, E., Zhang, P., & Feng, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783786 · Cited by 1
Chang, Y., Li, H., Liu, X., Li, X., Liu, J., Song, J., Fu, H., Xu, X. X., Wang, Y., Wang, Q., et al. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70974 · Cited by 1
Boyanova, S., Katsouri, L., Krupic, J., Hair, K., Wang, S., & Wiseman, F. K. (2026) · STAR Protocols · doi:10.1016/j.xpro.2026.104633 · Cited by 1
Metadata
- Authors
- Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S.
- Affiliations
- Indiana University Indianapolis (US)
- University of California, San Francisco (US)
- Banner Health (US)
- University of Southern California (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Brown University (US)
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 362-377
- ISSN
- 2274-5807 (ISSN-L)
- PMC
- PMC10313141
- OpenAlex
- W4360591479
- Cited by
- 961
- References
- 62
- Citations by year
- 2026: 335 · 2025: 305 · 2024: 249 · 2023: 71
- FWCI
- 170.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Journal of Prevention of Alzheimer s Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (R35AG71476, U01NS093334, P20GM109025, P30AG072959, P30 AG010133, R01AG053798, R01 AG057739)
- Alzheimer's Association (P30 AG010133)
- Alzheimer's Drug Discovery Foundation (P20GM109025)
- Eli Lilly and Company (P20GM109025)
- Biogen (P20GM109025)
- University of Southern California (P20GM109025)
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- BioClinica (P20GM109025)
- Sunovion
- Buck Institute for Research on Aging
- Prothena
- University of Oxford
- Eisai (P20GM109025)
- Novo Nordisk
- Shionogi
- H. Lundbeck A/S (P20GM109025)
- Grifols
- Nestec
- National Institutes of Health (RD005665)
- Genentech (P20GM109025)
- Allergan
- Avid Radiopharmaceuticals
- National Institute on Aging (AG010133, P30AG010133, U01AG057195, NIA U01 AG057195, R01AG053798, P20AG068053, NIA P30 AG010133, R01AG057739, R35AG71476, P30AG072959, P30AG072980, R35AG071476)
- National Institute of General Medical Sciences (P20GM109025)
- National Institute of Neurological Disorders and Stroke (U01NS093334)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- lecanemab, Alzheimer's disease, amyloid-related imaging abnormalities, amyloid plaques, mild cognitive impairment, early Alzheimer's disease, bleeding risk, anticoagulation, infusion reactions, monoclonal antibody therapy, caregiver-patient communication, clinical preparedness
- MeSH terms
- Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Apolipoprotein E4, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
